Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an oral formulation for systemic use. It treats a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, and skin and soft‑tissue infections, in adult and pediatric patients where appropriate. It is also incorporated into combination regimens for Helicobacter pylori eradication.

GNH USA supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with established logistics for timely delivery and regulatory support across multiple regions.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections of the respiratory tract, sinuses, and skin. - Community‑acquired pneumonia: reduces bacterial load and improves clinical outcomes in patients with susceptible organisms. - Acute bacterial sinusitis: alleviates infection symptoms and promotes sinus drainage. - Acute exacerbations of chronic bronchitis: shortens duration of worsening symptoms and reduces need for additional antibiotics. - Skin and soft tissue infections: eradicates causative bacteria and supports wound healing. - Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance as part of a multi‑drug regimen.

Clarithromycin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools that may be watery. - Abdominal pain: cramping or discomfort in the stomach area. - Taste disturbance: altered or metallic taste perception. - Headache: mild to moderate head pain. - Vomiting: occasional expulsion of stomach contents.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Clostridioides difficile‑associated diarrhea: severe colitis requiring medical attention. - QT interval prolongation: potential cardiac arrhythmias. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Cardiac arrhythmias: irregular heart rhythms beyond QT prolongation. - Anaphylaxis: life‑threatening systemic hypersensitivity.

Before prescribing clarithromycin, clinicians should consider several safety measures. - Assess renal and hepatic function: adjust use if organ impairment is present. - Monitor cardiac status: watch for QT prolongation, especially in patients with existing heart disease. - Review concomitant medications: avoid drugs that may interact adversely. - Use with caution in patients with known macrolide allergy: consider alternative agents. - Avoid use in pregnancy unless benefits outweigh risks: discuss with obstetric specialist. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Clarithromycin interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Cisapride and other QT‑prolonging agents: increased risk of cardiac arrhythmias. - Simvastatin and other CYP3A4 substrates: heightened risk of statin toxicity. - Pimozide: may cause severe cardiac effects. - Colchicine: risk of colchicine toxicity. - Ergot alkaloids: potential for ergotism.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Oral contraceptives: possible reduction in efficacy, advise backup contraception. - Theophylline: increased plasma levels, monitor for toxicity. - Carbamazepine: may reduce clarithromycin levels, assess therapeutic response. - Digoxin: potential increase in serum digoxin, monitor levels.